Hormonal factors and the risk of invasive ovarian cancer: A population-based case-control study

Fertility and Sterility

Volumn 82, Issue 1, 2004, Pages 186-195

  Pike, Malcolm C ^a   Pearce, Celeste L ^a   Peters, Ruth ^a   Cozen, Wendy ^a   Wan, Peggy ^a   Wu, Anna H ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

estrogen therapy; oral contraceptives; Ovarian cancer; parity

Indexed keywords

ETHINYLESTRADIOL; GESTAGEN; MESTRANOL; NORGESTREL; ORAL CONTRACEPTIVE AGENT;

ADULT; AGED; ARTICLE; BODY MASS; CANCER EPIDEMIOLOGY; CANCER PATIENT; CANCER RISK; CONFIDENCE INTERVAL; CONTROLLED STUDY; FEMALE; HORMONAL THERAPY; HUMAN; INTERVIEW; MAJOR CLINICAL STUDY; MENOPAUSE; NULLIPARA; OBESITY; ORAL CONTRACEPTION; OVARY CANCER; PARITY; POPULATION RESEARCH; PREGNANCY; PREVENTIVE MEDICINE; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME;

ADULT; BODY MASS INDEX; CASE-CONTROL STUDIES; CONTRACEPTIVES, ORAL; FEMALE; HORMONES; HUMANS; MATERNAL AGE; MIDDLE AGED; NEOPLASM INVASIVENESS; OVARIAN NEOPLASMS; PREGNANCY, HIGH-RISK; QUESTIONNAIRES; RISK ASSESSMENT;

EID: 3242786474     PISSN: 00150282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.fertnstert.2004.03.013     Document Type: Article

References (46)

1. Fathalla M.F. Factors in the causation and incidence of ovarian cancer. Obstet Gynecol Surv. 27:1972;751-768
2. Dubeau L. The cell of origin of ovarian epithelial tumors and the ovarian surface epithelium dogma does the emperor have no clothes? Gynecol Oncol. 72:1999;437-442
3. Newhouse M.L., Pearson R.M., Fullerton J.M., Boesen E.A.M., Shannon H.S. A case-control study of carcinoma of the ovary. Br J Prev Soc Med. 31:1977;148-153
4. Casagrande J.T., Pike M.C., Ross R.K., Louie E.W., Roy S., Henderson B.E. "Incessant ovulation" and ovarian cancer. Lancet. ii:1979;170-173
5. Cancer and Steroid Hormone Study (CASH) of the Centers for Disease Control and the National Institute of Child Health and Human Development. The reduction in the risk of ovarian cancer associated with oral contraceptive use. N Engl J Med. 316:1987;650-655
6. Collaborative Ovarian Cancer Group, Whittemore A.S., Harris R., Itnyre J. Characteristics relating to ovarian cancer risk. Collaborative analysis of 12 US-case-control studies. II. Invasive epithelial ovarian cancers in white women. Am J Epidemiol. 136:1992;1184-1203
7. Pike M.C. Age-related factors in cancers of the breast, ovary, and endometrium. J Chron Dis. 40:1987;59S-69S
8. Zhou H., Luo M., Schonthal A.H., Pike M.C., Stallcup M.R., Zheng W., et al. Influence of reproductive hormones on ovarian epithelial tumors I. Effect on cell cycle activity. Cancer Biol. 1:2002;300-306
9. Schildkraut J.M., Calingaert B., Marchbanks P.A., Moorman P.G., Rodriguez G.C. Impact of progestin and estrogen potency in oral contraceptives on ovarian cancer risk. J Natl Cancer Inst. 94:2002;32-38
10. McCluskey L.L., Dubeau L. Biology of ovarian cancer. Curr Opin Oncol. 9:1997;465-470
11. Breslow NE, Day NE. Statistical methods in cancer research. Vol. 1. The analysis of case-control studies. Lyon, France: IARC, 1980. IARC Scientific Publication 32
12. Henderson B.E., Gordon R.J., Menck H.R., SooHoo J., Martin S.J., Pike M.C. Lung cancer and air pollution in south-central Los Angeles County. Am J Epidemiol. 101:1975;477-488
13. Pike M.C., Peters R.K., Cozen W., Probst-Hensch N.M., Felix J.C., Wan P.C., et al. Estrogen-progestin replacement therapy and endometrial cancer. J Natl Cancer Inst. 89:1997;1110-1116
14. Dickey R.P., Stone S.C. Progestational potency of oral contraceptives. Obstet Gynecol. 47:1976;106-112
15. Purdie D.M., Bain C.J., Webb P.M., Whiteman D.C., Pirozzo S., Green A.C. Body size and ovarian cancer case-control study and systematic review (Australia). Cancer Causes Control. 12:2001;855-863
16. Whiteman D.C., Siskind V., Purdie D.M., Green A.C. Timing of pregnancy and the risk of epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev. 12:2003;42-46
17. Titus-Ernstoff L., Perez K., Cramer D.W., Harlow B.L., Baron J.A., Greenberg E.R. Menstrual and reproductive factors in relation to ovarian cancer risk. Br J Cancer. 84:2001;714-721
18. Risch H.A., Marrett L.D., Howe G.R. Parity, contraception, infertility, and the risk of epithelial ovarian cancer. Am J Epidemiol. 140:1994;585-597
19. Riman T., Dickman P.W., Nilsson S., Correia N., Nordlinder H., Magnusson C.M., et al. Risk factors for invasive epithelial ovarian cancer results from a Swedish case-control study. Am J Epidemiol. 156:2002;363-373
20. Ness R.B., Grisso J.A., Klapper J., Schlesselman J.J., Silberzweig S., Vergona R., et al. Risk of ovarian cancer in relation to estrogen and progestin dose and use characteristics of oral contraceptives. Am J Epidemiol. 152:2000;233-241
21. Royar J., Becher H., Chang-Claude J. Low-dose oral contraceptives protective effect on ovarian cancer risk. Int J Cancer. 95:2002;370-374
22. Irwin K.L., Weiss N.S., Lee N.C., Peterson H.B. Tubal sterilization, hysterectomy, and the subsequent occurrence of epithelial ovarian cancer. Am J Epidemiol. 134:1991;362-369
23. Hankinson S.E., Hunter D.J., Colditz G.A., Willett W.C., Stampfer M.J., Rosner B., et al. Tubal ligation, hysterectomy, and risk of ovarian cancer. J Am Med Assoc. 270:1993;2813-2818
24. Green A., Purdie D., Bain C., Siskind V., Russell P., Quinn M., et al. Tubal sterilisation, hysterectomy and decreased risk of ovarian cancer. Int J Cancer. 71:1997;948-951
25. Schildkraut J.M., Cooper G.S., Halabi S., Calingaert B., Hartge P., Whittemore A.S. Age at natural menopause and the risk of epithelial ovarian cancer. Obstet Gynecol. 98:2001;85-90
26. Garg P.P., Kerlikowske K., Subak L., Grady D. Hormone replacement therapy and the risk of epithelial ovarian carcinoma a meta-analysis. Obstet Gynecol. 92:1998;472-479
27. Coughlin S.S., Giustozzi A., Smith S.J., Lee N.C. A meta-analysis of estrogen replacement therapy and risk of epithelial ovarian cancer. J Clin Epidemiol. 53:2000;367-375
28. Rodriguez C., Patel A.V., Calle E.E., Jacob E.J., Thun M.J. Estrogen replacement therapy and ovarian cancer mortality in a large prospective study of US women. J Am Med Assoc. 285:2001;1460-1465
29. Lacey J.V., Mink P.J., Lubin J.H., Sherman M.E., Troisi R., Hartge P., et al. Menopausal hormone replacement therapy and risk of ovarian cancer. J Am Med Assoc. 288:2002;334-341
30. Riman T., Dickman P.W., Nilsson S., Correia N., Nordliner H., Magnusson C.M., et al. Hormone replacement therapy and the risk of invasive epithelial ovarian cancer in Swedish women. J Natl Cancer Inst. 94:2002;497-504
31. Weiss N.S., Lyon J.L., Krishnamurthy S., Dietert S.E., Liff J.M., Daling J.R. Non-contraceptive estrogen use and the occurrence of ovarian cancer. J Natl Cancer Inst. 68:1982;95-98
32. Cramer D.W., Hutchison G.B., Welch W.R., Scully R.E., Ryan K.J. Determinants of ovarian cancer risk. I. Reproductive experiences and family history. J Natl Cancer Inst. 71:1983;711-716
33. Lee NC, Wingo PA, Peterson HB, Rubin GL, Sattin RW. Estrogen therapy and the risk of breast, ovarian and endometrial cancer. In: Mastroianni L Jr, Paulsen CA, eds. Aging, reproduction and the climacteric. New York: Plenum Press, 1986. pp. 287-303
34. Risch H.A. Estrogen replacement therapy and risk of epithelial ovarian cancer. Gynecol Oncol. 63:1996;254-257
35. Purdie D.M., Bain C.J., Siskind V., Russell P., Hacker N.F., Ward B.G., et al. Hormone replacement therapy and risk of epithelial ovarian cancer. Br J Cancer. 81:1999;559-563
36. Sit A.S.Y., Modugno F., Weissfeld J.L., Berga S.L., Ness R.B. Hormone replacement therapy formulations and risk of epithelial ovarian carcinoma. Gynecol Oncol. 86:2002;118-123
37. Greenland S., Longnecker M.P. Methods for trend estimation from summarized dose-response data, with applications to meta-analysis. Am J Epidemiol. 135:1992;1301-1309
38. Kuper H., Cramer D.W., Titus-Ernstoff L. Risk of ovarian cancer in the United States in relation to anthropometric measures does the association depend on menopausal status? Cancer Causes Control. 13:2002;455-463
39. Lubin F., Chetrit A., Freedman L.S., Alfandry E., Fisher Y., Nitzan H., et al. Body mass index at age 18 years and during adult life and ovarian cancer risk. Am J Epidemiol. 157:2003;113-120
40. Fairfield K.M., Willett W.C., Rosner B.A., Manson J.E., Speizer F.E., Hankinson S.E. Obesity, weight gain, and ovarian cancer. Obstet Gynecol. 100:2002;288-296
41. Lukanova A., Toniolo P., Lundin E., Micheli A., Akhmedkhanov A., Biessy C., et al. Body mass index in relation to ovarian cancer a multi-centre nested case-control study. Int J Cancer. 99:2002;603-608
42. Rodriguez C., Calle E.E., Fakhrabadi-Shokoohi D., Jacobs E.J., Thun M.J. Body mass index, height, and the risk of ovarian cancer mortality in a prospective cohort of postmenopausal women. Cancer Epidemiol Biomarkers Prev. 11:2002;822-928
43. Schouten L.J., Goldbohm R.A., van den Brandt P.A. Height, weight, weight change, and ovarian cancer risk in the Netherlands cohort study on diet and cancer. Am J Epidemiol. 157:2003;424-433
44. Engeland A., Tretli S., Bjorge T. Height, body mass index, and ovarian cancer a follow-up of 1.1 million Norwegian women. J Natl Cancer Inst. 95:2003;1244-1248
45. Rodriguez G.C., Walmer D.K., Cline M., Krigman H., Lessey B.A., Whitaker R.S., et al. Effect of progestin on the ovarian epithelium of macaques cancer prevention through apoptosis? J Soc Gynecol Invest. 5:1998;271-276
46. Rodriguez G.C., Nagarsheth N.P., Lee K.L., Bentley R.C., Walmer D.K., Cline M., et al. Progestin-induced apoptosis in the Macaque ovarian epithelium differential regulation of transforming growth factor-β J Natl Cancer Inst. 94:2002;50-60